Dear Dr. LastName,

I wanted to share news with you that will impact some of your patients. I recently started testing patients with night vision complaints using the AdaptDx ProTM, which is a new technology that measures the speed of dark adaptation (how quickly your patient’s eyes adjust to dark environments), one of the earliest symptoms of age-related macular degeneration (AMD). With the aid of the AdaptDx Pro, we can identify patients with AMD at least 3 years before we can detect changes in the eye by retinal evaluation or optical coherence tomography (OCT).

Measuring dark adaptation speed will not only help us to identify AMD earlier in the disease process, but also prompt us to follow these patients more frequently. Upon diagnosis of AMD, patients will be educated on treatments including smoking cessation, lifestyle changes such as improved diet and exercise, tighter management of systemic conditions, supplementation with anti-oxidants and retinal light protection to slow disease progression. Ultimately, my goal is to diagnose neovascular AMD before significant vision loss occurs.

I will send you a letter when I confirm an early AMD diagnosis in any of our mutual patients. It is my hope that, working together, we can intervene earlier in the disease process to preserve our patients’ vision and quality of life.

Sincerely,

FirstName LastName, OD

Please visit the following website for more information about this exciting new technology:

<https://www.maculogix.com/adaptdx/improve-patient-care/>